Browse our 650+ Publications​

Latest Publications

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.

Munir T, et al.
Journal of Clinical Oncology
June 2023
Authors and Affiliates
Talha Munir, MBBS1 ; Carol Moreno, MD2; Carolyn Owen, MD3; George Follows, PhD4; Ohad Benjamini, MD5; Ann Janssens, MD, PhD6;Mark-David Levin, MD7 ; Anders Osterborg, MD, PhD8; Tadeusz Robak, MD, PhD9 ; Martin Simkovic, MD, PhD10 ; Don Stevens, MD11;Sergey Voloshin, MD, PhD12; Vladimir Vorobyev, PhD13 ; Munci Yagci, MD14; Loic Ysebaert, MD, PhD15 ; Keqin Qi, PhD16 ; Qianya Qi, PhD17;Lori Parisi, MPH17; Srimathi Srinivasan, PhD18 ; Natasha Schuier, MD19; Kurt Baeten, PhD20; Angela Howes, PhD21;Donne Bennett Caces, MD, PhD17; Carsten U. Niemann, MD, PhD22 ; and Arnon P. Kater, MD, PhD23 1 St James’s Hospital, Leeds, United Kingdom 2; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Research Leukaemia Research Institute, Barcelona, Spain3; Tom Baker Cancer Centre, Calgary, Canada 4;Addenbrookes Hospital, Cambridge, United Kingdom 5;Sheba Medical Center, Ramat Gan, Israel 6; UZ Leuven Gasthuisberg, Leuven, Belgium 7;Albert Schweitzer Hospital, Dordrecht, the Netherlands 8; Karolinska University Hospital, Stockholm, Sweden 9; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland 10; University Hospital Hradec Kralove, Hradec Kralove, Czech Republic 11;Norton Cancer Institute, Louisville, KY 12; Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia 13; S.P. Botkin Moscow City Clinical Hospital, Moscow, Russia 14; Gazi Universitesi Tip Fakultesi, Ankara, Turkey 15; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France 16; Janssen Research & Development, Titusville, NJ 17; Janssen Research & Development, Raritan, NJ 18; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA 19; Janssen Research & Development, Dusseldorf, Germany ¨20; Janssen Research & Development, Beerse, Belgium 21;Janssen Research & Development, High Wycombe, United Kingdom 22; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark 23; Amsterdam Medical Centers, University of Amsterdam, Amsterdam, the Netherlands

Teclistamab in Relapsed or Refractory Multiple Myeloma.

Moreau P, et al.
New England Journal of Medicine
June 2023
Authors and Affiliates
P. Moreau, A.L. Garfall, N.W.C.J. van de Donk, H. Nahi, J.F. San‑Miguel, A. Oriol, A.K. Nooka, T. Martin, L. Rosinol, A. Chari, L. Karlin, L. Benboubker, M.-V. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez‑López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, S. Girgis, S.X.W. Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R. Van Rampelbergh, A. Banerjee, J.D. Goldberg, R. Kobos, A. Krishnan, and S.Z. Usmani The Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Hospital Clínic, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona (L.R.), University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro del Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), and Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.) — all in Spain; Winship Cancer Institute, Emory University, Atlanta (A.K.N.); the University of California, San Francisco, San Francisco (T.M.), Stanford University School of Medicine, Stanford (S.S.), and City of Hope Comprehensive Cancer Center, Duarte (A.K.) — all in California; Mount Sinai School of Medicine (A.C.) and Memorial Sloan Kettering Cancer Center (S.Z.U.) — both in New York; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada (N.B.); Clinical Research Facility, National Institute for Health Research University College London Hospitals, NHS Foundation Trust, London (R.P.); the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany (B.B.); the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Antwerp (Y.O., R.V.R.) — both in Belgium; Janssen Research and Development, Raritan, NJ (L.P., D.T., M.J., J.D.G., R.K.); and Levine Cancer Institute– Atrium Health, Charlotte, NC (S.Z.U.).

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

Hill JA, et al.
May 2023
Authors and Affiliates
Joshua A Hill 1 2, Michael J Martens 3 4, Jo-Anne H Young 5, Kavita Bhavsar 3, Jianqun Kou 3, Min Chen 3, Lik Wee Lee 6, Aliyah Baluch 7, Madhav V Dhodapkar 8, Ryotaro Nakamura 9, Kristin Peyton 10, Zainab Shahid 11, Paul Armistead 12, Peter Westervelt 13, John McCarty 14, Joseph McGuirk 15, Mehdi Hamadani 16, Susan DeWolf 11, Kinga Hosszu 11, Elad Sharon 17, Ashley Spahn 18, Amir A Toor 14, Stephanie Waldvogel 18, Lee M Greenberger 19, Jeffery J Auletta 18 20, Mary M Horowitz 3, Marcie L Riches 3, Miguel-Angel Perales 11 21; 1 Vaccine and Infectious Disease, Fred Hutchinson Cancer Center, Seattle, WA, USA. 2 Department of Medicine, University of Washington, Seattle, WA, USA. 3 Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, WI, USA. 4 Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA. 5 University of Minnesota, Minneapolis, MN, USA. 6 Adaptive Biotechnologies Corp, Seattle, WA, USA. 7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 8 Emory University - School of Medicine, Atlanta, GA, USA. 9 City of Hope, Duarte, CA, USA. 10 The Emmes Company, Rockville, MD, USA. 11 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 University of North Carolina Medical Center, Chapel Hill, NC, USA. 13 Barnes-Jewish Hospital, Washington University, St. Louis, MO, USA. 14 Virginia Commonwealth University, Richmond, VA, USA. 15 University of Kansas, Lawrence, KS, USA. 16 Medical College of Wisconsin, Milwaukee, WI, USA. 17 National Cancer Institute, Bethesda, MD, USA. 18 National Marrow Donor Program/Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA. 19 The Leukemia and Lymphoma Society, Rye Brook, New York, NY, USA. 20 Nationwide Children's Hospital, Columbus, OH, USA. 21 Weil Cornell Medical College, New York, NY, USA.

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas LA, et al.
May 2023
Authors and Affiliates
Luis A. Rojas #1,2, Zachary Sethna #1,2, Kevin C. Soares 2,3, Cristina Olcese 2, Nan Pang 2, Erin Patterson 2, Jayon Lihm 4, Nicholas Ceglia 4, Pablo Guasp 1,2, Alexander Chu 4, Rebecca Yu 1,2, Adrienne Kaya Chandra 1,2, Theresa Waters 1,2, Jennifer Ruan 1,2, Masataka Amisaki 1,2, Abderezak Zebboudj 1,2, Zagaa Odgerel 1,2, George Payne 1,2, Evelyna Derhovanessian 5, Felicitas Müller 5, Ina Rhee 6, Mahesh Yadav 6, Anton Dobrin 7,8, Michel Sadelain 7,8, Marta Łuksza 9, Noah Cohen 10, Laura Tang 11, Olca Basturk 11, Mithat Gönen 12, Seth Katz 13, Richard Kinh Do13, Andrew S. Epstein 14, Parisa Momtaz 14, Wungki Park 3,14, Ryan Sugarman 14, Anna M. Varghese 14, Elizabeth Won 14, Avni Desai 14, Alice C. Wei 2,3, Michael I. D’Angelica 2,3, T. Peter Kingham 2,3, Ira Mellman 6, Taha Merghoub 15, Jedd D. Wolchok 15, Ugur Sahin 5, Özlem Türeci 5,16, Benjamin D. Greenbaum (corresponding author) 4,17, William R. Jarnagin 2,3, Jeffrey Drebin 2,3, Eileen M. O’Reilly 3,14, and Vinod P. Balachandran (corresponding author) 1,2,3; 1 Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY USA. 2 Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY USA. 3 David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY USA. 4 Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY USA. 5 BioNTech, Mainz, Germany. 6 Genentech, San Francisco, CA USA. 7 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY USA. 8 Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY USA. 9 Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA. 10 Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY USA. 11 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA. 12 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY USA. 13 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY USA. 14 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA. 15 Meyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY USA. 16 HI-TRON, Helmholtz Institute for Translational Oncology, Mainz, Germany. 17 Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY USA.

TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs

Genolet R, et al.
May 2023
Authors and Affiliates
Raphael Genolet 1,2,4,∗ Sara Bobisse 1,2, Johanna Chiffelle 1,2, Marion Arnaud 1,2, Rémy Petremand 1,2, Lise Queiroz 1,2, Alexandra Michel 1,2, Patrick Reichenbach 1, Julien Cesbron 1,2 Aymeric Auger 1,2, Petra Baumgaertner 1,2, Philippe Guillaume 1,2, Julien Schmidt 1,2, Melita Irving 1, Lana E. Kandalaft1,2, Daniel E. Speiser 1, George Coukos 1,3,∗∗ and Alexandre Harari 1,3,∗∗∗; 1 Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland. 2 Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland. Raphael Genolet: hc.vuhc@teloneg.leahpar; George Coukos: hc.vuhc@sokuoc.egroeg; Alexandre Harari: hc.vuhc@irarah.erdnaxela

Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.

Short NJ, et al.
American Journal of Hematology
May 2023
Authors and Affiliates
Nicholas J. Short1 | Elias Jabbour1 | Walid Macaron1 | Farhad Ravandi1 | Nitin Jain1 | Rashmi Kanagal-Shamanna2 | Keyur P. Patel2 | Sanam Loghavi2 | Fadi G. Haddad1 | Musa Yilmaz1 | Ghayas C. Issa1 | Partow Kebriaei3 | Steven M. Kornblau1 | Sarah Pelletier 1 | Wilmer Flores 1 | Jairo Matthews1 | Rebecca Garris1 | Hagop Kantarjian1 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Final Analysis of Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in the CANDOR Study.

Usmani SZ, et al.
Blood Advances
May 2023
Authors and Affiliates
Saad Z. Usmani,1 Hang Quach,2 Maria-Victoria Mateos,3 Ola Landgren,4 Xavier Leleu,5 David Siegel,6 Katja Weisel,7 Xiaomei Shu,8 Chuang Li,9 Meletios Dimopoulos10 1Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; 2University of Melbourne, St Vincent’s Hospital, Melbourne, VIC, Australia; 3University Hospital Salamanca/ISAI, Salamanca, Spain; 4Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States of America; 5CHU de Poitiers – La Miletrie/INSERM CIC 1402, Poitiers, France; 6John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, United States of America; 7University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 8Paraxel, Chengdu, China; 9Amgen Inc., Thousand Oaks, CA, United States of America; 10National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

Martin T, et al.
Blood Cancer Journal
May 2023
Authors and Affiliates
Thomas Martin 1,22, Meletios-Athanasios Dimopoulos 2, Joseph Mikhael 3, Kwee Yong 4, Marcelo Capra5, Thierry Facon6,Roman Hajek 7, Ivan Špička8, Ross Baker9, Kihyun Kim10, Gracia Martinez11, Chang-Ki Min12, Ludek Pour13, Xavier Leleu 14, Albert Oriol 15, Youngil Koh16, Kenshi Suzuki17, France Casca18, Sandrine Macé19, Marie-Laure Risse20 and Philippe Moreau21,22 1Department of Hematology, University of California at San Francisco, San Francisco, CA, USA. 2The National and Kapodistrian University of Athens, Athens, Greece. 3Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 4Department of Haematology, University College Hospital, London, UK. 5Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil. 6Department of Haematology, Lille University Hospital, Lille, France. 7Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. 8Department of Hematology, 1st Faculty of Medicine, Charles University andGeneral Hospital, Prague, Czech Republic. 9Perth Blood Institute, Murdoch University, Perth, Australia. 10Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 11Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo,Brazil. 12Department of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea. 13Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. 14Service d’Hématologie et Thérapie Cellulaire, CHU and CIC Inserm, 1402 Poitiers Cedex, France. 15Institut Josep Carreras and Institut Catala d’Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain. 16Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. 17Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan. 18Ividata Life Science, Levallois-Perret, France. 19Sanofi, R&D, Chilly-Mazarin, France. 20Sanofi, R&D, Vitry-sur-Seine, France. 21Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France. 22These authors contributed equally: Thomas Martin, PhilippeMoreau

Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.

Patel DA, et al.
April 2023
Authors and Affiliates
Dilan A. Patel, Fei Wan, Kathryn Trinkaus, Daniel G. Guy, Natasha Edwin, Marcus Watkins, Nancy L. Bartlett, Amanda Cashen, Todd A. Fehniger, Armin Ghobadi, Neha-Mehta Shah, Brad S. Kahl Washington University in St Louis School of Medicine, St Louis, MO, 63110
Previous Next